Key result
rPH-1 plus ISA70 adjuvant increases T cell and anti-ILTV antibodies versus rPH-1 alone in chickens.
Why the study?
To reduce the risk of adverse effects associated with live vaccines against infectious laryngotracheitis virus, the immunogenicity of a recombinant PH-1 domain of viral glycoprotein B was evaluated in chickens.
Does recombinant PH-1 domain of ILTV glycoprotein B induce immune responses in chickens?
Does recombinant PH-1 domain of ILTV glycoprotein B induce immune responses in chickens?
p-value: p=< 0.01
Recombinant PH-1 domain of ILTV glycoprotein B with ISA70 adjuvant effectively induces humoral and cellular immune responses in chickens, suggesting potential as a vaccine candidate.
rPH-1 shows immunogenicity in SPF chickens; leaves open protective efficacy and field utility as ILTV vaccine.
Infectious laryngotracheitis virus (ILTV) is a cause of main respiratory disease of chickens controlled through live attenuated vaccines. To reduce the risk of adverse effects associated with live vaccines, a recombinant vaccine expressing PH-1 domain of viral glycoprotein B was constructed using the pET expression system under isopropylthiogalactoside (IPTG) induction. The potential immunogenicity of recombinant PH-1 (rPH-1) was evaluated in chickens. Eight-week-old specific-pathogen-free chickens were intramuscularly administered two doses of rPH-1, 25 and 50 μg, alone or with a combination of ISA70 adjuvant. The humoral immune responses were determined up to 3 months postvaccination at 2 weeks apart. The T cell proliferation response was determined on day 28 after primary immunization. The vaccinated birds with rPH-1/ISA70 developed higher and constant-specific anti-ILTV enzyme-linked immunosorbent assay (ELISA) antibodies than in those vaccinated with rPH-1 alone. Coinjection of rPH-1 and adjuvant significantly (p < 0.01) increased the T cell proliferation responses. There were no significant differences in eliciting the immune responses in chickens immunized with the higher dose of the antigen than that with the lower dose. The data indicate the immunogenic efficiency of rPH-1 against ILTV. Vaccination with recombinant proteins offers a preventing option to control the ILTV infection and could be a candidate to replace current live vaccines.
No takes yet. Share an insight, caveat, or question.
Shahsavandi et al. (2021) studied Infectious laryngotracheitis virus (ILTV) infection. Recombinant PH-1 (rPH-1) with ISA70 adjuvant vs. rPH-1 alone was evaluated on Humoral immune responses and T cell proliferation response (p=< 0.01). Coinjection of recombinant PH-1 and ISA70 adjuvant significantly increased T cell proliferation responses (p < 0.01) and anti-ILTV antibodies compared to rPH-1 alone in chickens.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: